• PP 1: A Causal Probe of Src Kinase Signaling

  2026-09-17

  PP 1 is a selective Src family tyrosine kinase inhibitor for separating Lck, Fyn, Lyn, and RET-linked signaling from broader pathway effects. This article explains how to deploy PP 1 as a mechanistic assay tool while applying lessons from chemoproteomics and genetic validation in kinase research.

• (-)-Arctigenin in EV–NF-κB Assays

  2026-09-16

  Use (-)-Arctigenin as a dose-controlled pharmacological probe for LPS- and macrophage-EV-driven inflammatory signaling in breast cancer models. Its complementary MEK1 and NF-κB activity supports pathway triangulation, while careful solubility, vehicle, and EV controls help separate signaling effects from nonspecific cytotoxicity.

• p-Cresyl Sulfate: A Compartment-Aware Research Guide

  2026-09-16

  Explore how p-Cresyl sulfate, or p-tolyl hydrogen sulfate, can be used to connect uremic exposure with endothelial and biliary injury. This guide translates product chemistry and recent mechanistic evidence into better-controlled assays for cardiovascular, renal, and hepatobiliary research.

• AU-24118 and ABCB1 Resistance in Prostate Cancer

  2026-09-15

  This PNAS study introduces AU-24118, an orally bioavailable PROTAC degrader of mSWI/SNF ATPase components, and demonstrates tumor regression in preclinical castration-resistant prostate cancer models. It also identifies SMARCA4 mutations and ABCB1 overexpression as distinct acquired resistance mechanisms, with the ABCB1 inhibitor Zosuquidar restoring sensitivity to several PROTAC classes.

• Imatinib (STI571) Workflows for Kinase Research

  2026-09-15

  Build reproducible kinase-inhibition, proliferation, and differentiation assays with Imatinib (STI571), while separating pathway blockade from changes in kinase abundance. The workflow also shows how to use imatinib alongside the hypoxia-driven erythroid model reported in recent erythroleukemia research.

• ATRX-Deficient Glioma and RTK Inhibitor Sensitivity

  2026-09-14

  The reference study identifies ATRX loss as a potential determinant of sensitivity to multi-targeted receptor tyrosine kinase and PDGFR inhibitors in high-grade glioma cells. Its results also support evaluating RTK inhibitor–temozolomide combinations in an ATRX-aware manner, while emphasizing that genotype-stratified interpretation is essential for translational cancer research.

• PF-573228 FAK Inhibitor Workflow

  2026-09-14

  PF-573228 provides a practical way to test how FAK links matrix stiffness, focal adhesion signaling, migration, survival, and angiogenesis. This workflow translates dentinogenesis findings into controlled mechanobiology, cancer-cell motility, and endothelial assays with dose-aware troubleshooting.

• SAN-Plexus Assembloids Reveal Pacemaker Maturation

  2026-09-13

  This study develops human pluripotent stem cell-derived assembloids that combine sinoatrial node, cardiac ganglionated plexus, and atrial-like tissues to model neural control of pacemaker maturation and conduction. Integrated electrophysiology and human SAN spatial transcriptomics identify a prosaposin–GPR37 signaling axis as a candidate mechanism linking cardiac neurons with pacemaker development.

• Prestained Protein Marker: F4005 Workflow Guide

  2026-09-12

  The Prestained Protein Marker is a Triple color protein ladder for 10–250 kDa SDS-PAGE separation and Western blot protein size verification. F4005 uses visible recombinant protein bands, is EDTA free, and supports Phosbind SDS-PAGE and fluorescent membrane imaging workflows.

• Kir4.1–Panx3 Signaling in Orofacial Neuropathic Pain

  2026-09-11

  The reference study identifies a Kir4.1–ROS–p38 MAPK–Panx3 axis in trigeminal satellite glial cells that contributes to orofacial neuropathic pain after infraorbital nerve injury. Its combination of cell-specific genetic manipulation, behavioral testing, and pathway rescue experiments provides a mechanistic framework for connecting glial potassium-channel dysfunction with trigeminal sensitization.

• RWJ 67657: Designing Better p38α Assays

  2026-09-11

  RWJ 67657 is a selective p38α/β inhibitor for studying TNF-alpha regulation. This guide shows how to distinguish catalytic blockade from phosphatase-assisted signal resetting when designing biochemical, cellular, and inflammatory disease assays.

• PD98059 MEK Inhibitor: Applied Research Guide

  2026-09-10

  Use PD98059 as a reversible pathway probe to connect MEK–ERK1/2 activity with proliferation, differentiation, and apoptosis outcomes. This guide translates leukemia-cell findings into practical assay workflows while distinguishing ERK1/2 effects from the parallel ERK5 pathway and ischemia-model observations.

• Thiazovivin ROCK Inhibitor Workflow Guide

  2026-09-10

  Thiazovivin is a ROCK inhibitor used to support fibroblast reprogramming, induced pluripotent stem cell generation, and human embryonic stem cell survival after trypsinization. This dossier-based guide covers preparation, controls, and troubleshooting for stem cell research; it does not establish clinical, diagnostic, or universal dosing use.

• Dual-Action p38α Inhibitors and WIP1 Dephosphorylation

  2026-09-09

  The reference preprint identifies a mechanism in which selected p38α kinase inhibitors both suppress catalytic activity and accelerate activation-loop dephosphorylation by the phosphatase WIP1. Structural and biochemical results show that inhibitor-stabilized activation-loop conformations expose the phospho-threonine, suggesting a route to improving kinase inhibitor potency and selectivity through control of phosphatase access.

• Fasudil (HA-1077) HCl: Causal Assay Design

  2026-09-09

  Fasudil (HA-1077) HCl offers a practical downstream ROCK perturbation for testing whether cytoskeletal signaling contributes to Hippo-associated phenotypes. This article translates quercetin–cataract findings into a causal assay framework while separating evidence-based observations from new experimental hypotheses.

8474 records 1/565 page Next 12345 下5页 Last page